Important breakthrough for Danish biotech fledgling  

2005.05.20
Biotech fledgling Enkam Pharmaceuticals, based in Copenhagen, has developed a peptide drug, FGL, for the treatment of Alzheimer's disease which has shown very promising results in animal tests

Biotech fledgling Enkam Pharmaceuticals, based in Copenhagen, has developed a peptide drug, FGL [Fibroblast Growth loop – Ed], for the treatment of Alzheimer's disease which has shown very promising results in animal tests. Morten Albrechtsen, director of Enkam says that its drug has shown in animal tests that memory and learning were improved. Peter Johannsen, MD at the Danish National Hospital and a researcher in Alzheimer's Disease calls the drug discovery an important breakthrough.

Enkam Pharmaceuticals was established in 2000 as a spin-off from the University of Copenhagen. The biotech company is developing short peptide drugs, both of endogenous origin and synthetic, for the treatment of CNS diseases. Elisabeth Bock, Professor in Cell Biology who has conducted important research in the CNS area, is part of Enkam's management. The news is reported by national daily newspaper Jyllands-Posten.

Link > Enkam Pharmaceuticals 

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×